CUE
Cue Biopharma, Inc.
Price Chart
Latest Quote
$28.46
+1.73 (+6.47%)
Current Price
| Previous Close | $26.73 |
| Open | $26.50 |
| Day High | $28.70 |
| Day Low | $25.69 |
| Volume | 157,726 |
Stock Information
| Shares Outstanding | 4.20M |
| Total Debt | $3.44M |
| Cash Equivalents | $17.44M |
| Revenue | $32.73M |
| Net Income | $-19.52M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $119.54M |
| EPS (TTM) | $-4.49 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $101.14M |
| Sales | $32.73M |
| Income | $-19.52M |
| Book/sh | $6.64 |
| Cash/sh | $4.15 |
| Employees | 29 |
Financial Ratios
| Quick Ratio | 3.34 |
| Current Ratio | 3.57 |
| Debt/Eq | 15.92 |
Returns & Margins
| ROA | -46.08% |
| ROE | -138.52% |
| Gross Margin | -6.45% |
| Operating Margin | -94.32% |
| Profit Margin | -59.65% |
Ownership
| Insider Ownership | 8.55% |
| Institutional Ownership | 17.68% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -59.29 |
| P/S | 3.65 |
| P/B | 4.29 |
Analyst Data
| Recommendation | none |
| Target Price | $115.00 |
Technical Indicators
| SMA20 | $25.46 |
| SMA50 | $23.49 |
| SMA200 | $16.96 |
| RSI | 62.27 |
| ATR | 3.8869 |
| Shares Float | 3.61M |
| Short Float | 7.51% |
| Short Ratio | 0.23 |
| Rel Volume | 2.34 |
Performance History
| Week | +5.06% |
| Month | +40.20% |
| Quarter | +259.34% |
| 6 Months | +131.38% |
| YTD | +181.50% |
| Year | +63.56% |
| 3 Years | -76.16% |
| 5 Years | -92.88% |
| 10 Years | -91.84% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $28.46 | 197,800 |
| 2026-06-17 | $26.73 | 86,400 |
| 2026-06-16 | $23.89 | 63,000 |
| 2026-06-15 | $25.80 | 78,700 |
| 2026-06-12 | $24.53 | 86,600 |
| 2026-06-11 | $27.09 | 43,600 |
| 2026-06-10 | $27.86 | 37,500 |
| 2026-06-09 | $30.44 | 47,700 |
| 2026-06-08 | $29.08 | 47,400 |
| 2026-06-05 | $29.46 | 92,200 |
| 2026-06-04 | $29.64 | 56,600 |
| 2026-06-03 | $26.91 | 67,900 |
| 2026-06-02 | $28.62 | 119,700 |
| 2026-06-01 | $24.07 | 138,800 |
| 2026-05-29 | $21.90 | 87,600 |
| 2026-05-28 | $22.64 | 107,000 |
| 2026-05-27 | $20.43 | 32,700 |
| 2026-05-26 | $20.03 | 72,700 |
| 2026-05-22 | $21.47 | 61,200 |
| 2026-05-21 | $20.10 | 164,800 |
| 2026-05-20 | $20.43 | 180,400 |
| 2026-05-19 | $20.30 | 135,400 |
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
đ° Latest News
Cue Biopharma (CUE) Appoints Lucinda Warren as Interim President and CEO
Insider Monkey âĸ 2026-04-20T14:15:48Z
The VIX Sharply Reverses and Points Back Towards 30 After Failed Peace Negotiations
24/7 Wall St. âĸ 2026-04-13T14:16:29Z
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates
Zacks âĸ 2025-11-12T22:25:03Z
CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates
Zacks âĸ 2025-11-07T22:55:01Z
Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates
Zacks âĸ 2025-11-06T23:00:03Z
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates
Zacks âĸ 2025-11-05T23:35:02Z
Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates
Zacks âĸ 2025-10-30T12:20:02Z
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
Zacks âĸ 2025-08-12T21:10:02Z
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
Zacks âĸ 2025-08-08T11:45:02Z
scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates
Zacks âĸ 2025-08-07T22:00:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $27,466,000 | $9,287,000 | $5,490,000 | $1,245,000 |
| Operating Revenue | $27,466,000 | $9,287,000 | $5,490,000 | $1,245,000 |
| Expenses | ||||
| Interest Expense | $357,000 | $796,000 | $1,245,000 | $713,000 |
| Total Expenses | $53,987,000 | $50,880,000 | $57,482,000 | $54,747,000 |
| Other Income Expense | $-31,000 | $93,000 | $-157,000 | $277,000 |
| Net Non Operating Interest Income Expense | $450,000 | $826,000 | $1,416,000 | $215,000 |
| Interest Expense Non Operating | $357,000 | $796,000 | $1,245,000 | $713,000 |
| Operating Expense | $53,987,000 | $50,880,000 | $57,482,000 | $54,747,000 |
| General And Administrative Expense | $16,244,000 | $14,585,000 | $16,680,000 | $16,169,000 |
| Rent Expense Supplemental | - | - | $716,000 | $899,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-26,602,000 | $-40,674,000 | $-50,733,000 | $-53,010,000 |
| Net Interest Income | $450,000 | $826,000 | $1,416,000 | $215,000 |
| Interest Income | $807,000 | $1,622,000 | $2,661,000 | $928,000 |
| Normalized Income | $-26,577,510 | $-40,767,000 | $-50,576,000 | $-53,287,000 |
| Net Income From Continuing And Discontinued Operation | $-26,602,000 | $-40,674,000 | $-50,733,000 | $-53,010,000 |
| Total Operating Income As Reported | $-26,552,000 | $-41,500,000 | $-52,149,000 | $-53,225,000 |
| Net Income Common Stockholders | $-26,602,000 | $-40,674,000 | $-50,733,000 | $-53,010,000 |
| Net Income | $-26,602,000 | $-40,674,000 | $-50,733,000 | $-53,010,000 |
| Net Income Including Noncontrolling Interests | $-26,602,000 | $-40,674,000 | $-50,733,000 | $-53,010,000 |
| Net Income Continuous Operations | $-26,602,000 | $-40,674,000 | $-50,733,000 | $-53,010,000 |
| Pretax Income | $-26,102,000 | $-40,674,000 | $-50,733,000 | $-53,010,000 |
| Special Income Charges | $-31,000 | $93,000 | $-157,000 | $277,000 |
| Interest Income Non Operating | $807,000 | $1,622,000 | $2,661,000 | $928,000 |
| Operating Income | $-26,521,000 | $-41,593,000 | $-51,992,000 | $-53,502,000 |
| Per Share | ||||
| Diluted EPS | $-8.40 | $-21.60 | $-33.30 | $-44.70 |
| Basic EPS | $-8.40 | $-21.60 | $-33.30 | $-44.70 |
| Other | ||||
| Tax Effect Of Unusual Items | $-6,510 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-22,234,000 | $-37,621,000 | $-45,895,000 | $-50,768,000 |
| Total Unusual Items | $-31,000 | $93,000 | $-157,000 | $277,000 |
| Total Unusual Items Excluding Goodwill | $-31,000 | $93,000 | $-157,000 | $277,000 |
| Reconciled Depreciation | $3,480,000 | $2,350,000 | $3,436,000 | $1,806,000 |
| EBITDA (Bullshit earnings) | $-22,265,000 | $-37,528,000 | $-46,052,000 | $-50,491,000 |
| EBIT | $-25,745,000 | $-39,878,000 | $-49,488,000 | $-52,297,000 |
| Diluted Average Shares | $3,157,725 | $1,877,611 | $1,525,159 | $1,188,304 |
| Basic Average Shares | $3,157,725 | $1,877,611 | $1,525,159 | $1,188,304 |
| Diluted NI Availto Com Stockholders | $-26,602,000 | $-40,674,000 | $-50,733,000 | $-53,010,000 |
| Tax Provision | $500,000 | $0 | - | $0 |
| Gain On Sale Of Ppe | $-31,000 | $93,000 | $-157,000 | $277,000 |
| Research And Development | $37,743,000 | $36,295,000 | $40,802,000 | $38,578,000 |
| Selling General And Administration | $16,244,000 | $14,585,000 | $16,680,000 | $16,169,000 |
| Other Gand A | $16,244,000 | $14,585,000 | $16,680,000 | $5,889,000 |
| Rent And Landing Fees | - | - | $716,000 | $899,000 |
| Salaries And Wages | - | - | $8,925,000 | $9,381,000 |
| Impairment Of Capital Assets | - | - | - | $-276,633 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $26,432,000 | $17,499,000 | $37,085,000 | $65,682,000 |
| Total Assets | $42,212,000 | $32,191,000 | $61,530,000 | $91,283,000 |
| Total Non Current Assets | $5,229,000 | $7,053,000 | $10,076,000 | $14,096,000 |
| Other Non Current Assets | $248,000 | $257,000 | $268,000 | $278,000 |
| Non Current Prepaid Assets | $666,000 | $1,955,000 | $2,690,000 | $3,116,000 |
| Current Assets | $36,983,000 | $25,138,000 | $51,454,000 | $77,187,000 |
| Other Current Assets | $1,309,000 | $805,000 | $955,000 | $841,000 |
| Prepaid Assets | $1,093,000 | $929,000 | $287,000 | - |
| Receivables | $7,445,000 | $945,000 | $1,698,000 | $57,000 |
| Taxes Receivable | $1,899,000 | $0 | - | - |
| Accounts Receivable | $5,546,000 | $945,000 | $1,698,000 | $57,000 |
| Cash Cash Equivalents And Short Term Investments | $27,136,000 | $22,459,000 | $48,514,000 | $76,289,000 |
| Cash And Cash Equivalents | $27,136,000 | $22,459,000 | $48,514,000 | $51,614,000 |
| Debt | ||||
| Total Debt | $4,197,000 | $8,876,000 | $14,695,000 | $19,316,000 |
| Long Term Debt And Capital Lease Obligation | $2,286,000 | $1,003,000 | $7,364,000 | $14,053,000 |
| Current Debt And Capital Lease Obligation | $1,911,000 | $7,873,000 | $7,331,000 | $5,263,000 |
| Current Debt | - | $4,333,000 | $3,963,000 | $1,963,000 |
| Other Current Borrowings | - | $4,333,000 | $3,963,000 | $1,963,000 |
| Long Term Debt | - | - | $4,202,000 | $8,035,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $15,780,000 | $14,692,000 | $24,445,000 | $25,601,000 |
| Total Non Current Liabilities Net Minority Interest | $2,286,000 | $1,003,000 | $7,364,000 | $14,053,000 |
| Current Liabilities | $13,494,000 | $13,689,000 | $17,081,000 | $11,548,000 |
| Current Deferred Liabilities | $5,335,000 | $85,000 | $2,112,000 | $0 |
| Payables And Accrued Expenses | $5,465,000 | $3,919,000 | $5,419,000 | $4,012,000 |
| Payables | $4,637,000 | $2,823,000 | $3,501,000 | $2,731,000 |
| Other Payable | $689,000 | - | - | - |
| Accounts Payable | $3,948,000 | $2,823,000 | $3,501,000 | $2,731,000 |
| Non Current Deferred Liabilities | - | - | - | - |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $26,432,000 | $17,499,000 | $37,085,000 | $65,682,000 |
| Total Equity Gross Minority Interest | $26,432,000 | $17,499,000 | $37,085,000 | $65,682,000 |
| Stockholders Equity | $26,432,000 | $17,499,000 | $37,085,000 | $65,682,000 |
| Retained Earnings | $-368,466,000 | $-341,864,000 | $-301,190,000 | $-250,457,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | $0 | $-96,000 |
| Other Equity Adjustments | - | - | - | $-96,000 |
| Other | ||||
| Ordinary Shares Number | $3,220,707 | $2,060,636 | $1,573,837 | $1,434,751 |
| Share Issued | $3,220,707 | $2,060,636 | $1,573,837 | $1,434,751 |
| Tangible Book Value | $26,432,000 | $17,499,000 | $37,085,000 | $65,682,000 |
| Invested Capital | $26,432,000 | $21,832,000 | $45,250,000 | $75,680,000 |
| Working Capital | $23,489,000 | $11,449,000 | $34,373,000 | $65,639,000 |
| Capital Lease Obligations | $4,197,000 | $4,543,000 | $6,530,000 | $9,318,000 |
| Total Capitalization | $26,432,000 | $17,499,000 | $41,287,000 | $73,717,000 |
| Additional Paid In Capital | $394,801,000 | $359,301,000 | $338,228,000 | $316,192,000 |
| Capital Stock | $97,000 | $62,000 | $47,000 | $43,000 |
| Common Stock | $97,000 | $62,000 | $47,000 | $43,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $2,286,000 | $1,003,000 | $3,162,000 | $6,018,000 |
| Current Deferred Revenue | $5,335,000 | $85,000 | $2,112,000 | $0 |
| Current Capital Lease Obligation | $1,911,000 | $3,540,000 | $3,368,000 | $3,300,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $783,000 | $1,812,000 | $2,219,000 | $2,273,000 |
| Current Accrued Expenses | $828,000 | $1,096,000 | $1,918,000 | $1,281,000 |
| Net PPE | $4,315,000 | $4,841,000 | $7,118,000 | $10,702,000 |
| Accumulated Depreciation | $-3,663,000 | $-3,680,000 | $-3,616,000 | $-4,242,000 |
| Gross PPE | $7,978,000 | $8,521,000 | $10,734,000 | $14,944,000 |
| Leases | $118,000 | $118,000 | $118,000 | $118,000 |
| Other Properties | $7,585,000 | $8,155,000 | $10,392,000 | $5,246,000 |
| Machinery Furniture Equipment | $275,000 | $248,000 | $224,000 | $377,000 |
| Properties | $0 | $0 | $0 | $0 |
| Buildings And Improvements | - | - | $6,323,000 | $9,203,000 |
| Other Short Term Investments | - | - | $0 | $24,675,000 |
| Non Current Deferred Revenue | - | - | - | - |
| Construction In Progress | - | - | - | - |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-21,864,000 | $-36,395,000 | $-39,961,000 | $-41,977,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-21,687,000 | $-36,329,000 | $-39,961,000 | $-41,806,000 |
| Cash Flow From Continuing Operating Activities | $-21,687,000 | $-36,329,000 | $-39,961,000 | $-41,806,000 |
| Operating Gains Losses | $31,000 | $-93,000 | $157,000 | $4,000 |
| Investing Activities | ||||
| Capital Expenditure | $-177,000 | $-66,000 | - | $-171,000 |
| Investing Cash Flow | $75,000 | $32,000 | $25,002,000 | $-24,610,000 |
| Cash Flow From Continuing Investing Activities | $75,000 | $32,000 | $25,002,000 | $-24,610,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $30,791,000 | $14,224,000 | $13,387,000 | $39,300,000 |
| Financing Cash Flow | $26,291,000 | $10,243,000 | $11,860,000 | $53,659,000 |
| Cash Flow From Continuing Financing Activities | $26,291,000 | $10,243,000 | $11,860,000 | $53,659,000 |
| Net Common Stock Issuance | $30,791,000 | $14,224,000 | $13,387,000 | $39,300,000 |
| Common Stock Issuance | $30,791,000 | $14,224,000 | $13,387,000 | $39,300,000 |
| Net Other Financing Charges | - | - | - | $-341,000 |
| Other | ||||
| Repayment Of Debt | $-4,500,000 | $-3,999,000 | $-2,000,000 | $0 |
| Interest Paid Supplemental Data | $214,000 | $669,000 | $1,003,000 | $570,000 |
| End Cash Position | $27,290,000 | $22,611,000 | $48,665,000 | $51,764,000 |
| Beginning Cash Position | $22,611,000 | $48,665,000 | $51,764,000 | $64,521,000 |
| Changes In Cash | $4,679,000 | $-26,054,000 | $-3,099,000 | $-12,757,000 |
| Proceeds From Stock Option Exercised | $0 | $18,000 | $473,000 | $4,700,000 |
| Net Issuance Payments Of Debt | $-4,500,000 | $-3,999,000 | $-2,000,000 | $10,000,000 |
| Net Long Term Debt Issuance | $-4,500,000 | $-3,999,000 | $-2,000,000 | $10,000,000 |
| Long Term Debt Payments | $-4,500,000 | $-3,999,000 | $-2,000,000 | $0 |
| Net Investment Purchase And Sale | $212,000 | $0 | $25,000,000 | $-24,445,000 |
| Sale Of Investment | $16,500,000 | $0 | $25,000,000 | $5,000,000 |
| Purchase Of Investment | $-16,288,000 | $0 | $0 | $-29,445,000 |
| Net PPE Purchase And Sale | $-137,000 | $32,000 | $2,000 | $-165,000 |
| Sale Of PPE | $40,000 | $98,000 | $2,000 | $6,000 |
| Purchase Of PPE | $-177,000 | $-66,000 | $0 | $-171,000 |
| Change In Working Capital | $-3,295,000 | $-4,925,000 | $-934,000 | $356,000 |
| Change In Other Working Capital | $5,250,000 | $-2,027,000 | $2,112,000 | $-645,000 |
| Change In Other Current Liabilities | $-2,572,000 | $-1,987,000 | $-2,788,000 | $-735,000 |
| Change In Payables And Accrued Expense | $517,000 | $-1,907,000 | $1,358,000 | $-988,000 |
| Change In Accrued Expense | $-1,297,000 | $-1,229,000 | $588,000 | $-1,071,000 |
| Change In Payable | $1,814,000 | $-678,000 | $770,000 | $83,000 |
| Change In Account Payable | $1,125,000 | $-678,000 | $770,000 | $83,000 |
| Change In Prepaid Assets | $10,000 | $243,000 | $25,000 | $-361,000 |
| Change In Receivables | $-6,500,000 | $753,000 | $-1,641,000 | $3,085,000 |
| Changes In Account Receivables | $-4,601,000 | $753,000 | $-1,641,000 | $3,085,000 |
| Other Non Cash Items | $167,000 | $167,000 | $167,000 | $-137,000 |
| Stock Based Compensation | $4,744,000 | $6,846,000 | $8,180,000 | $9,496,000 |
| Amortization Of Securities | $-212,000 | $0 | $-234,000 | $-321,000 |
| Depreciation Amortization Depletion | $3,480,000 | $2,350,000 | $3,436,000 | $1,806,000 |
| Depreciation And Amortization | $3,480,000 | $2,350,000 | $3,436,000 | $1,806,000 |
| Depreciation | $3,480,000 | $2,350,000 | $3,436,000 | $1,806,000 |
| Gain Loss On Sale Of PPE | $31,000 | $-93,000 | $157,000 | $4,000 |
| Net Income From Continuing Operations | $-26,602,000 | $-40,674,000 | $-50,733,000 | $-53,010,000 |
| Issuance Of Debt | - | - | $0 | $10,000,000 |
| Long Term Debt Issuance | - | - | $0 | $10,000,000 |
| Change In Other Current Assets | - | - | - | $0 |
Fetched: 2026-06-15